Maxcyte (MXCT) Accumulated Depreciation (2020 - 2026)

Maxcyte (MXCT) has 7 years of Accumulated Depreciation data on file, last reported at $18.3 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 16.97% year-over-year to $18.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.3 million (up 16.97% YoY) and the FY2025 annual result came in at $17.3 million, up 27.02% from the prior year.
• Accumulated Depreciation grew to $18.3 million in Q1 2026 per MXCT's latest filing, from $17.3 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $18.3 million in Q1 2026 and bottomed at $4.8 million in Q1 2022.
• The 5-year median for Accumulated Depreciation is $11.4 million (2024), against an average of $11.2 million.
• The widest annual swing landed in 2023, when Accumulated Depreciation jumped 65.6%; it then climbed 16.97% in 2026.
• Tracing MXCT's Accumulated Depreciation over 5 years: stood at $6.3 million in 2022, then jumped by 63.92% to $10.3 million in 2023, then soared by 32.14% to $13.6 million in 2024, then gained by 27.02% to $17.3 million in 2025, then increased by 5.83% to $18.3 million in 2026.
• Per Business Quant, the three latest MXCT Accumulated Depreciation figures stand at $18.3 million (Q1 2026), $17.3 million (Q4 2025), and $17.0 million (Q3 2025).

Peer Comparison